Influence of manufacturing practices on quality of pharmaceutical products manufactured in Kenya

East African Medical Journal

Volumn 81, Issue 6, 2004, Pages 287-292

  Orwa, J A ^a   Keter, L K ^a   Ouko, S P A ^a   Kibwage, I O ^b   Rukunga, G M ^a  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CROSS-SECTIONAL STUDY; DRUG FORMULATION; DRUG INDUSTRY; EPIDEMIOLOGY; HEALTH CARE QUALITY; HUMAN; KENYA; METHODOLOGY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; STANDARD; STATISTICS;

CROSS-SECTIONAL STUDIES; DRUG COMPOUNDING; DRUG INDUSTRY; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; KENYA; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY OF HEALTH CARE;

EID: 27744545911     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: 10.4314/eamj.v81i6.9177     Document Type: Article

References (20)

1. Kirking, D.M., Ascione, F.J., Gaither, C.A. and Welage, L.S. Economics and structure of the generic pharmaceutical industry. J. Amer. Pharm. Assoc. 2001; 41:578-584.
2. WHO. Countering the counterfeits. WHO Drug Information. 1987; 1:195-196
3. WHO. Expert Committee on specifications for Pharmaceutical preparations, Annex 1. Good manufacturing practices for pharmaceutical products. WHO Technical Report Series, No.823. pp 14-79.
4. WHO. Guidelines for developing national drug policies. WHO. Geneva, 1988.
5. Jayasuriya, D.C. Regulation of pharmaceuticals in developing countries. Strategies for assurance of drug quality, safety, and efficacy. WHO, Geneva 1985, p.p 51-62.
6. World Health Organization. Counterfeiting the counterfeits. WHO Drug Information. 1987; 1:195-196.
7. Hogerzeil, H.V., De Goerje, M.J. and Abu-Reid 1.0. Stability of essential drugs in Sudan. Lancet. 1991; 338:754.
8. Arya, S.C. Inadvertent supply of substandard drugs. World Health Forum. 1995; 16:269.
9. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Annex I. Good manufacturing practices for pharmaceutical products. WHO Technical Report Series. No; 823. Pp 14-79.
10. Munio, S. A vision of the pharmaceutical industry. Methods Find. Exp. Clin. Pharamacol. 1998; 20 (Suppl. A): 5-9.
11. Shakoor, O., Taylor, R.B. and Behrens, R.H. Assessment of the incidence of substandard drugs in developing countries. Trop. Med. Int. Hlth. 1997; 2:839-845.
12. Antony, P.G.R. and Temu-Justin. M. The quality of drugs manufactured in Tanzania. East Cent. Afr. J. Pharm. Sci. 1999; 2:45-49.
13. Taylor, R.B., Shakoor, O., Behrens, R.H., et al. Pharmacopoeil quality of drugs supplied by Nigerian pharmacies. Lancet. 2001; 357:1933-1936.
14. Risha, P.G., Shewiyo, D., Msami. A., et al. In vitro evaluation of the quality of essential drugs on the Tanzanian market. Trop. Med. Int. Hlth. 2002; 7:701-707.
15. Kibwage, I.O., Ogeto, J.O., Maitai, C.K., Rutere, G., Thuranira, J. and Ochieng, A. Drug quality control work in DARU: Observations during 1983-1986. East Afr. Med. J. 1992; 69:577-580.
16. Mang'era, K.O., Rutere, G.K., Thuranira, J.K., et al. Drug quality control work at Drug Analysis Research Unit: Observations during 1987-1990. Pharm. J. Kenya. 1992; 4:66-70.
17. Kibwage, I.O., Thuranira, J.K., Gathu, Lily, et al. Drug quality control work in Drug Analysis and Research Unit: Observations during 1991-1995. East Cent. Afr. J. Pharm. Sci. 1991; 2:32-36.
18. Amugune, B.K.M. Development and validation of a liquid chromatography method for the simultaneous analysis of anticonvulsant drugs. M.Pharm Thesis, University of Nairobi, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, April 2002.
19. United States Pharmacopoeia 24, United States Pharmacopoeial Convention, Rockville, MD, 1998.
20. British Pharmacopoeia, Her Majesty's Stationary Office, London, UK, 2000.